Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 93-99 |
| Journal | Archives of Biochemistry and Biophysics |
| Volume | 475 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 15 Jul 2008 |
Fingerprint
Cite this
}
Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. / Kranendonk, Michel; Duarte, Maria Paula Amaro de Castilho; Rueff, J.
In: Archives of Biochemistry and Biophysics, Vol. 475, No. 2, 15.07.2008, p. 93-99.Research output: Contribution to journal › Article
TY - JOUR
T1 - Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase
AU - Kranendonk, Michel
AU - Duarte, Maria Paula Amaro de Castilho
AU - Rueff, J.
PY - 2008/7/15
Y1 - 2008/7/15
N2 - Objective: To develop evidence-based recommendations for the management of fibromyalgia syndrome. Methods: A multidisciplinary task force was formed representing 11 European countries. The design of the study, including search strategy, participants, interventions, outcome measures, data collection and analytical method, was defined at the outset. A systematic review was undertaken with the keywords "fibromyalgia'', "treatment or management'' and "trial''. Studies were excluded if they did not utilise the American College of Rheumatology classification criteria, were not clinical trials, or included patients with chronic fatigue syndrome or myalgic encephalomyelitis. Primary outcome measures were change in pain assessed by visual analogue scale and fibromyalgia impact questionnaire. The quality of the studies was categorised based on randomisation, blinding and allocation concealment. Only the highest quality studies were used to base recommendations on. When there was insufficient evidence from the literature, a Delphi process was used to provide basis for recommendation. Results: 146 studies were eligible for the review. 39 pharmacological intervention studies and 59 non-pharmacological were included in the final recommendation summary tables once those of a lower quality or with insufficient data were separated. The categories of treatment identified were antidepressants, analgesics, and "other pharmacological'' and exercise, cognitive behavioural therapy, education, dietary interventions and "other non-pharmacological''. In many studies sample size was small and the quality of the study was insufficient for strong recommendations to be made. Conclusions: Nine recommendations for the management of fibromyalgia syndrome were developed using a systematic review and expert consensus.
AB - Objective: To develop evidence-based recommendations for the management of fibromyalgia syndrome. Methods: A multidisciplinary task force was formed representing 11 European countries. The design of the study, including search strategy, participants, interventions, outcome measures, data collection and analytical method, was defined at the outset. A systematic review was undertaken with the keywords "fibromyalgia'', "treatment or management'' and "trial''. Studies were excluded if they did not utilise the American College of Rheumatology classification criteria, were not clinical trials, or included patients with chronic fatigue syndrome or myalgic encephalomyelitis. Primary outcome measures were change in pain assessed by visual analogue scale and fibromyalgia impact questionnaire. The quality of the studies was categorised based on randomisation, blinding and allocation concealment. Only the highest quality studies were used to base recommendations on. When there was insufficient evidence from the literature, a Delphi process was used to provide basis for recommendation. Results: 146 studies were eligible for the review. 39 pharmacological intervention studies and 59 non-pharmacological were included in the final recommendation summary tables once those of a lower quality or with insufficient data were separated. The categories of treatment identified were antidepressants, analgesics, and "other pharmacological'' and exercise, cognitive behavioural therapy, education, dietary interventions and "other non-pharmacological''. In many studies sample size was small and the quality of the study was insufficient for strong recommendations to be made. Conclusions: Nine recommendations for the management of fibromyalgia syndrome were developed using a systematic review and expert consensus.
KW - ESCHERICHIA-COLI MTC
KW - BIOACTIVATION ACTIVITIES
KW - STIMULATORY ROLE
KW - DISORDERED STEROIDOGENESIS
KW - polymorphism
KW - NADPH-FLAVODOXIN REDUCTASE
KW - NADPH-cytochrome P450 oxidoreductase
KW - adverse drug reactions
KW - Antley-Bixler syndrome
KW - cytochrome P450
KW - CYP1A2
KW - drug-metabolizing enzymes
KW - GENETIC-VARIATION
KW - P450 1A2
KW - MUTAGENICITY TESTER STRAIN
KW - protein-protein interaction
KW - MUTANT P450 OXIDOREDUCTASE
KW - HUMAN CYP1A2
KW - POR
KW - CELL EXPRESSION SYSTEM
U2 - 10.1016/j.abb.2008.04.014
DO - 10.1016/j.abb.2008.04.014
M3 - Article
VL - 475
SP - 93
EP - 99
JO - Archives of Biochemistry and Biophysics
JF - Archives of Biochemistry and Biophysics
SN - 0003-9861
IS - 2
ER -